UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2022

bluebird bio, Inc.
(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-35966**	**13-3680878**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
60 Binney Street, Cambridge, MA		**02142**
(Address of Principal Executive Offices)		**(Zip Code)**

Registrant's Telephone Number, Including Area Code: (339) 499-9300

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	BLUE	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

bluebird bio, Inc. intends to provide investors with an update of its anticipated 2022 regulatory and commercialization milestones across its beta-thalassemia, cerebral adrenoleukodystrophy, and sickle cell disease programs. A copy of the slide that will be used in presentations with investors is being furnished as Exhibit 99.1, which is incorporated herein by reference.

The information in this Current Report on Form 8-K pursuant to Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation slide by bluebird bio, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 18, 2022

bluebird bio, Inc.

By: /s/ Helen C. Fu
Helen C. Fu
Senior Vice President, General Counsel and Secretary

planned 2022 milestones – focus on regulatory milestones and commercialization

Beta-thalassemia

- *Ad Comm*
  DATE TO BE ANNOUNCED
- *FDA PDUFA date*
  AUGUST 19, 2022
- *Commercial launch*
  2022

Cerebral Adrenoleukodystrophy

- *Ad Comm*
  DATE TO BE ANNOUNCED
- *FDA PDUFA date*
  SEPTEMBER 16, 2022
- *Commercial launch*
  2022

Sickle Cell Disease

- *Complete manufacturing of commercial drug product validation lots*
  MID-2022
- *Confirm vector and drug product analytical comparability*
  Q4 2022
- *BLA submission*
  Q1 2023
  Currently evaluating what impact, if any, partial clinical hold may have on BLA target submission date